A Phase I, Multi-center Study to Determine the Effect of Fluzoparib on Pharmacokinetics of Caffeine, S-Warfarin, Omeprazole, Midazolam, Repaglinide and Bupropion in Patients With Recurrent Ovarian Cancer
Latest Information Update: 17 Aug 2023
At a glance
- Drugs Fuzuloparib (Primary) ; Bupropion; Caffeine; Midazolam; Omeprazole; Repaglinide; Vitamin K; Warfarin
- Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 10 Aug 2023 Status changed from active, no longer recruiting to completed.
- 23 Nov 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 23 Nov 2022 Planned primary completion date changed from 1 Oct 2021 to 1 Dec 2022.